ATAI Investor Day Presentation Deck

Key considerations for future studies atai LIFE SCIENCES Study HV PK Scopolamine Cognitive Challenge Cognitive Impairment Associated with Schizo Peripheral Diabetic Neuropathy Cognitive Impairment Associated with Schizo ● N=48 N=23 N=32 N=180 N=X Phase 1 7 Day Multiple Dose DB Placebo, 4x ΧΟ Cognition Cognition Open Label, 2 Day Phase 2 Cognition Double Blind Placebo XO, 1 month, 5 month ext Cognition Double Blind Placebo Safety /PK ✓ ✓ Target Engaged ✓ ✓ ✓ Initial CIAS study: confirmed safety, target engagement & cognitive response Next study: demonstrate statistically significant improvement in cognition Key considerations: dose, effect size & treatment duration Optimum dose range: 20 mg - 80 mg TID Pro-cognitive: Cohen's d effect sizes of -0.2 - 1.0+ (verbal learning, symbol coding) Durations tested: single dose to 4 weeks TID Biphasic | 41

View entire presentation